Fig. 7From: Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysisThe mechanism of Sora and Sim co-treatment in LM3-SR cells. Sim can enhance the sensitivity of LM3-SR cells to Sora by suppressing the HIF-1α/PPAR-γ/PKM2 axis, leading to the down-regulation of PKM2 expression in the nucleus and cytoplasm, thereby inhibiting glycolysis, proliferation and promote apoptosis in LM3-SR cellsBack to article page